In relation to this, dMMR and MSI-H have a high predictive value [96,115], while somatic mutations such as STK11/LKB1 and KEAP1 are prognostic of poor outcomes but not predictive [158] in terms of response to therapies with checkpoint inhibitors in lung adenocarcinoma. The gene discussed is STK11; the disease is lung adenocarcinoma.